RT Journal Article
SR Electronic
T1 Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 782
OP 791
DO 10.3899/jrheum.131250
VO 41
IS 4
A1 Laura C. Coates
A1 Oliver FitzGerald
A1 Philip J. Mease
A1 Dafna D. Gladman
A1 Vibeke Strand
A1 Niti Goel
A1 Ina Campbell
A1 Gerald Krueger
A1 Neil J. McHugh
A1 Philip S. Helliwell
YR 2014
UL http://www.jrheum.org/content/41/4/782.abstract
AB This module reflected work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to develop and validate composite disease activity measures in psoriatic arthritis (PsA). At the Outcome Measures in Rheumatology (OMERACT) 8 Meeting, a core set of domains to be assessed in randomized controlled trials (RCT) and longitudinal observational studies of PsA was agreed upon. At OMERACT 10, 5 proposed composite responder definitions for PsA were reviewed and discussed, including new data from the GRACE (GRAppa Composite Exercise) study. At OMERACT 11, ongoing retrospective analyses of RCT data using the 3 proposed measures (Composite Psoriatic Disease Activity Index, Psoriatic Arthritis Disease Activity Score, and Arithmetic Mean of the Desirability Function) were discussed in detail. There was agreement that developing composite outcome measures for use in RCT and longitudinal observational studies in PsA was important. Concerns were expressed regarding development of a single measure that encompassed diverse domains, such as joint counts, quality of life (QOL), and disability measures. It was emphasized that the use of any composite measure should include the ability to differentiate between activity in individual domains, such as enthesitis or psoriasis, such that the effect of each could be assessed independently. It was also agreed that patients would be systematically involved in further development and refinement of composite measures. Future plans include qualitative work with patients to explore their experience of disease activity and statistical modeling to explore how each of the proposed measures will perform in different disease subgroups.